Circio Holding ASA announces substantially oversubscribed preliminary result of the rights issue
Summary by AI BETAClose X
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Oslo, Norway, 29 January 2026 – Circio Holding ASA (OSE: CRNA) a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces preliminary results of the rights issue of up to NOK 50 million in gross proceeds (the “Rights Issue”).
The subscription period for the Rights Issue expired today, 29 January 2026, at 16:30 CET. The Rights Issue attracted strong interest from existing and new investors and was oversubscribed by more than 50%. As approved by the EGM on 12 January 2026, to cover all pre-subscriptions in full a private placement of approximately NOK 15 million will be executed in parallel with the Rights Issue. This will bring the total gross proceeds from the transactions to approximately NOK 65 million.
"The high demand for participation in the rights issue is a direct result of the technological breakthroughs Circio made during 2025, which led to a fully funded R&D collaboration with a global pharmaceutical company," said Damian Marron, Chair of the Board of Directors of Circio. "This new capital puts Circio in a robust financial position and will enable us to accelerate the circVec R&D activities and strengthen our scientific team in Stockholm. Combined with the rich pipeline of upcoming development milestones, we are now very well positioned to build further value for all our stakeholders in 2026".
The Rights Issue was led by long-term shareholders Høse AS, Star Kapital AS and Bækkelaget Holding AS, who jointly subscribed for approximately 30% of the Rights Issue. Members of Circio's board of directors and management jointly subscribed for approximately NOK 1.8 million, including NOK 400,000 from CEO, Dr. Erik Digman Wiklund.
"With strong support from both existing and new shareholders and Board and management, Circio now takes the next step on the journey to build the leading circular RNA expression platform company," said Dr. Erik Digman Wiklund, CEO of Circio. "The NOK 65 million raised in the oversubscribed transactions secure funding well into 2027, and the associated warrant structure is expected to prolong our financial runway to the second half of 2027. This strengthened foundation allows me and the talented Circio team to fully focus on further enhancing the circVec platform, forging novel partnerships and advancing our in-house programs in gene and cell therapy towards the clinic.”
The Rights Issue raises NOK 50 million in gross proceeds by issuance of 50,000,000 offer shares (the "Offer Shares"), at a subscription price of NOK 1.00 per share. The Rights Issue was 88.4% covered at launch by pre-subscriptions of NOK 24.2 million (48.4%) and a guarantee undertaking of NOK 20 million (40%). Subscribers in the Rights Issue will, without additional consideration, receive one warrant (the "Warrants") for every Offer Share allocated and paid by them.
The final allocation of the Offer Shares will take place tomorrow, on 30 January 2026, in accordance with the allocation criteria set out in the resolution made by the general meeting on 12 January 2026 and the securities note dated 13 January 2026 (the “Securities Note”, and together with a registration document dated on 1 October 2025, a registration document supplement and summary dated on 13 January 2026, the “Prospectus”). The Prospectus is available on the Company's website: https://www.circio.com/en/rightsissue2026/.
The final result of the Rights Issue, as well as information relating to the parallel private placement, will be published shortly thereafter. Final allocation of Offer Shares and the corresponding subscription amount to be paid by each subscriber, are expected to be available during the course of tomorrow, on 30 January 2026.
The payment date for the Offer Shares is 3 February 2026.
Latest directors dealings
- 53 minutes ago Croda International
- 1 hour ago Diageo
- 1 hour ago IMI
- 2 hours ago Softcat
- 5 hours ago Tertiary Minerals